Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report

Abstract Mesenchymal–epithelial transition (MET) exon 14 (METex14) skipping mutation is a rare (3%–4%) driver mutation in non‐small cell lung cancer (NSCLC). Tepotinib, a selective MET inhibitor, has shown promise in treating METex14 skipping‐mutated NSCLC. However, its feasibility for perioperative...

Description complète

Détails bibliographiques

Auteurs principaux:	Rongzhen Li, Xiaoyan Liu, Yan Xu, Jing Zhao, Wei Zhong, Xiaoxing Gao, Minjiang Chen, Mengzhao Wang
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2024-11-01
Collection:	Thoracic Cancer
Sujets:	MET exon 14 skipping mutation neoadjuvant non‐small cell lung cancer tepotinib
Accès en ligne:	https://doi.org/10.1111/1759-7714.15459
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!